Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals — Investor Presentation (August 2019)

46 slides from Constellation Pharmaceuticals's investor presentation, Aug 7, 2019

  1. Slide 1: Developing Next-Generation Epigenetic Treatments for Cancer Patients

    August 7, 2019 Developing Next-Generation Epigenetic Treatments for Cancer Patients Corporate Overview Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company’s product candidates, the anticipated benefits of

  3. Slide 3: Constellation Highlights

    Constellation Highlights Two wholly owned clinical programs: CPI-0610 (BET) and CPI-1205 (EZH2) CPI-0610 has possible disease-modifying effects in myelofibrosis CPI-1205 has been well tolerated and active in clinical studies in combination with ARS inhibitors in prostate cancer CPI-0209 expands the

  4. Slide 4: Multiple Near-Term Opportunities for Success

    * Metastatic castration-resistant prostate cancer Multiple Near-Term Opportunities for Success Product Candidates Indications Preclinical Phase 1 Phase 2 Phase 3 Milestones BET Inhibitor CPI-0610 2L Myelofibrosis 1L Myelofibrosis Interim Ph 2 data at ASCO/EHA Additional update in 4Q19 EZH2 Franchise

  5. Slide 5: Vision for 2019: A Year of Data

    Vision for 2019: A Year of Data 2019 Transition into a Late-Stage Oncology Development Company with an Exciting Pipeline of Development and Discovery Programs Generate positive POC and begin planning for pivotal registration studies with CPI-0610 and CPI-1205 Expand our EZH2 franchise by advancing C

  6. Slide 6: Epigenetics: Instructions for Genetic Code

    Epigenetics: Instructions for Genetic Code Tumor Cells MDSC NK Cell T Cell Focused on Three Distinct Classes That Chemically Modify Chromatin Tumor Microenvironment Target Transcriptional Networks That Result in Cell Death Re-program Immune Cells to Overcome Resistance to Cancer Immunotherapies Tran

  7. Slide 7: CPI-0610

    CPI-0610

  8. Slide 8: Control of Key Pathways Leads to Opportunity in Myelofibrosis

    Control of Key Immune, Fibrotic, and Oncogenic Pathways Leads to Opportunity in Myelofibrosis (MF) BET Family of Proteins … Enhancer TSS BRD4 Transcription Factor … Fibrosis TGF-β target genes Immune Signaling NF-κB target genes Cancer Genetics MYC, BCL2

  9. Slide 9: In Vivo Support for BET Inhibition Enhancing JAK Inhibition in MF

    Kleppe et al., 2018 Cancer Cell In Vivo Support for BET Inhibition Enhancing JAK Inhibition in MF BET Inhibitor + Ruxolitinib Led to Synergistic Reduction in Spleen Improved Bone Marrow Fibrosis Score Vehicle 1–2+ JQ1 (BETi) 1+ Ruxolitinib 1+ Combo 0 * * * * Bar graph showing spleen weights (mg) of

  10. Slide 10: Multiple Positioning Options for CPI-0610

    2L: Discontinue ruxolitinib Symptomatic MF 1L: Treatment with ruxolitinib 2L: Continue on ruxolitinib Myelofibrosis Patient Journey CPI-0610 + Rux Combo Diseased Bone Marrow Diseased Bone Marrow Diseased Bone Marrow Diseased Bone Marrow Multiple Positioning Options for CPI-0610 Disease Progression C

  11. Slide 11: Mechanism of Potential Disease Modification in Myelofibrosis

    Reduce Inflammation and Suppress Cells in the Bone Marrow That Drive MF (Megakaryocytes) Mechanism of Potential Disease Modification in Myelofibrosis BET Signaling Differentiation of Myeloid Cells into Megakaryocytes Pro-Inflammatory Cytokines (e.g., IL-8) JAK/STAT Signaling STAT STAT Cytoplasm Nucl

  12. Slide 12: CPI-0610 is a Potential Best-in-Class BET Inhibitor

    Potent and selective inhibitor of BET proteins Treated 138 patients in Phase 1 trials of various hematologic malignancies Preliminary clinical activity observed: Potentially disease modifying in MF (Phase 2) Lymphoma – e.g., ABC-DLBCL (Phase 1) Signals of potentially differentiated safety profile Ph

  13. Slide 13: Unmet Needs for a Disease-Modifying Therapy in MF

    * Based on preliminary data ** Full-year 2018 earnings releases of Incyte and Novartis *** Constellation estimate Working to Meet Unmet Needs for a Disease-Modifying Therapy That Impacts All Four Hallmarks of MF Hallmarks of Myelofibrosis JAKi’s CPI-0610* Spleen Volume Constitutional Symptoms Anemia

  14. Slide 14: MANIFEST Study Design Overview

    Data cutoff April 17, 2019 TD = Transfusion Dependent; TI = Transfusion Independent; SVR = Spleen Volume Response Cohorts 1A/1B and Cohorts 2A/2B will apply a Simon-2 stage design MANIFEST Study Design Overview Cohort 1A: TD n = up to 16 Cohort 1B: Non-TD n = up to 25 CPI-0610 Mono No longer on ruxo

  15. Slide 15: Baseline Demographics and Disease Characteristics

    Baseline Demographics and Disease Characteristics Parameter Cohort 1A 0610 Mono TD (n=2) Cohort 1B 0610 Mono Non-TD (n=8) Cohort 2A 0610 + Rux TD (n=16) Cohort 2B 0610 + Rux Non-TD (n=15) Cohort 3 0610 + Rux JAKi Naïve (n=3) TOTAL (n=44) Age Median (range) 68 (67, 69) 70 (46, 80) 72.5 (41, 83) 66 (4

  16. Slide 16: Treatment Duration

    Treatment Duration Total 44 patients enrolled 39 patients active on treatment; 5 patients discontinued Evaluable patients population Safety: Received C1D1 treatment – n=44 SVR: Baseline and one post-baseline data available – n=16 @ 12 weeks; n=12 @ 24 weeks TSS: Baseline TSS data available – n=11 @

  17. Slide 17: Summary of CPI-0610 Data Update from ASCO/EHA 2019

    Data cutoff April 17, 2019 *Please see poster A Phase 2 Study of CPI-0610…, which was presented at ASCO on June 3, 2019, in the Investors & Media/Presentations section of http://www.constellationpharma.com Summary of CPI-0610 Data Update from ASCO/EHA 2019 14 of 16 (88%) patients achieve spleen redu

  18. Slide 18: Best Spleen Volume Reduction

    Data cutoff April 17, 2019 *Patient ineligible for ruxolitinib due to very low hemoglobin Best Spleen Volume Reduction (n=16) 14 of 16 evaluable patients had spleen volume reductions Median change of -19.2% Spleen volume reduction observed in 4 of 4 evaluable non-TD monotherapy MF patients (depicted

  19. Slide 19: Improvements in Symptoms

    Data cutoff April 17, 2019 Improvements in Symptoms Best % Total Symptom Score (TSS) Improvement (n=11) Best Patient Global Impression of Change (PGIC) Observed (n=16) Improvement in TSS observed in 100% of patients 6 of 11 (55%) patients achieve > 50% improvement in TSS Improvement in PGIC observed

  20. Slide 20: Fibrosis Score Improvements Observed

    Data cutoff April 17, 2019 HMR = High Molecular Risk; Patients with one of these mutations: ASXL1, EZH2, IDH1/2 and SRSF2 Bone marrow evaluable population: Baseline reading available and at least one reading at or after 24 weeks – 10 of 44 patients Fibrosis Score Improvements Observed in Monotherapy

  21. Slide 21: Two Transfusion-Dependent Patients Converted to Transfusion Independence

    Data cutoff April 17, 2019 Two Transfusion-Dependent Patients Converted to Transfusion Independence Patient 11-246: CPI-0610 + Ruxolitinib, CALR Mutation Patient 11-252: CPI-0610 + Ruxolitinib, JAK2, TET2, SRSF2 and U2AF1 Mutations Patients no longer anemic Hemoglobin increase sustained for >69 week

  22. Slide 22: Improvement in Hemoglobin

    Data cutoff April 17, 2019 Improvement in Hemoglobin Mean Hemoglobin Levels by Treatment Regimen Substantial increase in hemoglobin is observed in CPI-0610 monotherapy patients With CPI-0610 + ruxolitinib combination, observed improvement in hemoglobin is delayed Patients potentially need to overcom

  23. Slide 23: Hematologic Improvements with CPI-0610 Monotherapy

    Patient 11-247, Non-TD, CPI-0610 Monotherapy, ASXL1 and CALR mutations Hematologic Improvements with CPI-0610 Monotherapy H&E Reticulin Baseline: MF Gr 3 C17: MF Gr 2 Patient Global Impression Change (PGIC) Bone Marrow Effects Platelets Normalization, Hb Improvement Resistant to Ruxolitinib; increas

  24. Slide 24: Reduction in Pro-inflammatory Cytokine Levels

    Reduction in Pro-inflammatory Cytokine Levels Cytokine reductions observed in MF patients with CPI-0610 monotherapy or combo with ruxolitinib Data cutoff April 17, 2019

  25. Slide 25: Treatment Emergent Adverse Events (TEAE)

    Treatment Emergent Adverse Events (TEAE) Treatment Emergent Adverse Event All Grade n=44 (n, %) ≥3 Grade* n=44 (n, %) Blood and Lymphatic System Disorders Anemia 2 (4.5) 2 (4.5) Thrombocytopenia 3 (6.8) 2 (4.5) Neutropenia 1 (2.3) 1 (2.3) Investigations Platelet Count Decreased 3 (6.8) 2 (4.5) Blood

  26. Slide 26: Effects on Platelet Levels

    Data cutoff April 17, 2019 Effects on Platelet Levels CPI-0610 Monotherapy (n=10) No Patients with Grade 3 Thrombocytopenia CPI-0610 + Ruxolitinib (n=34) 4 of 34 Patients with Grade 3 Thrombocytopenia CPI-0610 monotherapy demonstrated minimal, non-cumulative, and manageable thrombocytopenia Combinat

  27. Slide 27: Key Takeaways from ASCO/EHA 2019 Update

    Key Takeaways from ASCO/EHA 2019 Update Activity across all four hallmarks of myelofibrosis: spleen, symptoms, hematologic function, and bone marrow fibrosis CPI-0610-driven activity in ruxolitinib-resistant patients as monotherapy and as an add-on to ruxolitinib Substantial symptom and spleen impro

  28. Slide 28: Potential Paths to Registration for CPI-0610

    *SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. Mesa, R., et al. J Clin Oncol 2017: 35(34):3844-3850. ^COMFORT-1: A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis Verstovsek, S., et al;

  29. Slide 29: CPI-1205 and CPI-0209 EZH2 Franchise

    CPI-1205 and CPI-0209 EZH2 Franchise

  30. Slide 30: EZH2 Inhibition Offers Broad Therapeutic Potential

    EZH2 “Writer” Activity Suppresses Gene Transcription EZH2 Inhibition Offers Broad Therapeutic Potential Polycomb Repressive Complex 2 (PRC2)… … Methylates Histone H3 at Lysine 27 (K27) EZH2 SUPPRESSED TRANSCRIPTION Acquired Drug Resistance: EZH2 mediates gene silencing that diminishes response to ex

  31. Slide 31: Model for EZH2 Role in Prostate Cancer

    Yu et al., Cancer Research 2007 *Signature of H3K27me3-occupied EZH2 target genes repressed in metastatic relative to clinically localized prostate cancer and benign prostate tissue Model for EZH2 Role in Prostate Cancer EZH2 Gene Signature* Predicts Outcomes in Prostate Cancer 0 2 4 6 8 10 1.0 0.9

  32. Slide 32: EZH2 Synergy with Androgen Receptor Signaling

    *Bradley, WD, et al., ”EZH2 Inhibition as an Effective Treatment for Metastatic Castration-Resistant Prostate Cancer,” presentation at 2018 EORTC/NCI/AACR meeting EZH2 Synergy with Androgen Receptor Signaling (ARS) CPI-1205 Intensifies Gene Expression Effects of Enzalutamide in Prostate Cancer Cells

  33. Slide 33: Current Treatment Paradigm in mCRPC

    Current Treatment Paradigm in mCRPC mCRPC 1st Line Abiraterone or Enzalutamide 2nd Line Enzalutamide or Abiraterone (Poor Activity) 3rd Line Chemotherapy or Palliative Care CPI-1205 may enhance the activity of ARS inhibitors and reduce need for chemotherapy Pre-Metastatic Prostate Cancer

  34. Slide 34: 2L mCRPC Patients Suffer Poor Response Rate and Short Time to Progression

    2L mCRPC Patients Treated with Abiraterone or Enzalutamide Suffer Poor Response Rate and Short Time to Progression* GOAL Treat with CPI-1205 combination therapy to achieve deeper and more durable responses > PSA30 = 6% > PSA50 = 4% > PSA80 = 0% TTP = 1.6 months > PSA30 = 43% > PSA50 = 31% > PSA80 =

  35. Slide 35: ProSTAR Trial Design

    Note: In ProSTAR, abiraterone is dosed in combination with prednisone Phase 2 Initiated ProSTAR Trial Design Enzalutamide + CPI-1205 (Progressed on Abiraterone) n ~ 35 Enzalutamide Alone (Progressed on Abiraterone) n ~ 35 vs. Primary endpoint: Response rate PSA reduction, CTC reduction, ORR Enzaluta

  36. Slide 36: Resolution of Bone Metastases

    *Continued on CPI-1205 monotherapy after cycle 1 Resolution of Bone Metastases Baseline Cycle 4 Day 1 CPI-1205 + Enzalutamide* Example Patient 1

  37. Slide 37: Objective Response by CT Scan

    Objective Response by CT Scan February 2018 Baseline: December 2017 CPI-1205 + Enzalutamide Example Patient 2

  38. Slide 38: ProSTAR Phase 1b Conclusions

    CPI-1205 observed to be well-tolerated and clinically active Recommended Phase 2 dose of 800 mg three times daily Patients’ PSA responses tended to be deeper (e.g., PSA80) and more durable than expected with ARSi alone Activity observed in combo with abiraterone, which has poor 2L responses, or enza

  39. Slide 39: Significant PSA Reduction in Heavily Pre-Treated Patient

    Significant PSA Reduction in Heavily Pre-Treated and Refractory Patient Experience with a Compassionate-Use Patient 3,000 2,500 2,000 1,500 1,000 500 12 agents prior to CPI-1205, including second-generation androgen inhibitors, chemotherapy, PARP inhibitors, tyrosine kinase inhibitors, checkpoint in

  40. Slide 40: CPI-1205 EZH2 Franchise Summary

    CPI-1205 EZH2 Franchise Summary Preclinical synergy with androgen receptor signaling (ARS) inhibitors ProSTAR Phase 1b demonstrates well-tolerated combinations and evidence of activity with either enzalutamide or abiraterone ProSTAR Phase 2 started Best-in-class potential with more comprehensive cov

  41. Slide 41: CPI-0209: Second-Generation EZH2 Inhibitor

    Lymphoma Xenograft – Mutated EZH2 Model Once-Daily Treatment Resulted in Rapid and Durable Tumor Regression CPI-0209: Second-Generation EZH2 Inhibitor CPI-0209 May Provide More Comprehensive EZH2 Coverage, Expanding Addressable Populations Cessation of treatment Prostate Cancer Xenograft – ARV7+ Mod

  42. Slide 42: CPI-0209 Preclinical Activity in Bladder Cancer

    CPI-0209 Preclinical Activity in Bladder Cancer Tumor volume (mm3) Relative tumor volume (% change) Days Post Grouping Days Post Grouping CPI-0209 Causes Tumor Regression in ARID1A Mutant Bladder Cancer Xenografts CPI-0209 Is More Efficacious Than Cisplatin Single Agent Treatment

  43. Slide 43: Discovery Platform Fueling the Pipeline

    Discovery Platform Fueling the Pipeline Innate Adaptive Alter aberrant gene expression within cancer cells Increase tumor immunogenicity Re-program immune cells to overcome resistance to cancer immunotherapies Tumor Cells Immune Cells Discovery Programs Targeting Epigenetic Regulators on the Tumor a

  44. Slide 44: 2019 – Year of Data: Potential Value Creation Catalysts

    2019 –Year of Data Potential Value Creation Catalysts 2018 –Year of Execution 1H 2018 Complete crossover financing Expand enrollment in ProSTAR Initiate ORIOn-E Select 2nd generation EZH2 inhibitor candidate (CPI-0209) 2H 2018 Complete IPO Activate additional sites in US, Canada / EU for CPI-0610 in

  45. Slide 45: Strong Cash Position

    Cash, cash equivalents and marketable securities as of June 30, 2019, of $98.1 million Current cash, cash equivalents and marketable securities expected to fund operations until late Q3 2020, including: Ongoing clinical trials to determine efficacy and safety of CPI-1205 and CPI-0610 necessary to be

  46. Slide 46: Management Team

    Management Team Jigar Raythatha President and CEO Emma Reeve SVP & Chief Financial Officer Adrian Senderowicz, M.D. SVP & Chief Medical Officer Patrick Trojer, PhD SVP & Chief Scientific Officer Karen Valentine SVP, Chief Legal Officer & General Counsel Jessica Christo SVP & Chief Product Developmen

Constellation Pharmaceuticals — Investor Presentation (August 2019) on 6ix